In this online, self-learning activity:
Renal cell carcinoma (RCC) is a cancer that is borne and takes root in the nephrons and is responsible for the vast majority – 85% – of all renal cancers. With risk factors that include smoking, obesity, cadmium exposure, older age, and genetics, the five year survival rate of those afflicted with kidney cancer overall is 68%. In part because there are not any clear early symptoms associated with kidney cancer, RCC is discovered predominantly after it has already progressed to advanced stages, with the brain, bones, lungs, and liver serving as some of the most common sites of metastases. RCC’s treatment depends on its stage and size, with surgeryutilized for localized tumors and systemic therapy a mainstay of care for metastatic disease.
RCC has many treatment options, both targeted and non-targeted. The former, including monoclonal antibodies and other forms of immunotherapy, is now a standard of care, although angiogenesis inhibition is also an area of consideration. Emerging evidence is also suggesting ways in which biomarkers and radiographic indicators of response might shape the course of care.
The following healthcare professionals: medical oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with RCC.
Commercial Support Disclosure: This activity is supported by educational grants from BTG.
Learners may participate in this activity free of charge.
Release Date: September 11, 2019 -- Expiration Date: September 11, 2021
Faculty: Nazli Dizman, MD
Definition and epidemiology of RCC:
Clinical Features of RCC [Learning Objective #1]:
Emerging, immuno- and monoclonal therapy in RCC: within and beyond treatment guidelines [Learning Objectives #2, 3, 4, & 5]
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Nazli Dizman, M.D. has no relevent financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevent financial disclosures.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.